Will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
Interesting topics presented at ESMO 2017
Car brakes: PD-1/PD-L1 molecular pathway explained
Overview of urothelial carcinoma treatment landscape – the promise of immunotherapy
Durvalumab: the new standard of care for NSCLC?